CI Global Health Sciences Corporate Class

Series F USD
 

Fund overview

This fund invests primarily in equity and equity-related securities of companies around the world that specialize in the health care or medical industry.

Fund details

description of elementelement value
Inception date August 2000
CAD Total net assets ($CAD)
As at 2025-09-29
$139.8 million
NAVPS
As at 2025-10-22
$26.9401
MER (%)
As at 2025-03-31
1.24
Management fee (%) 0.90
Asset class Sector Equity
Currency USD
Minimum investment $500 initial/$25 additional
Distribution frequency Quarterly
Last distribution $0.5033

Risk rating1

  • Low
  • Low to medium
  • Medium
  • Medium to high
  • High

FUND CODES

F 324
A ISC 301
DSC SO* 401
LL SO 1401
P 90324
*No new purchases directly into switch only funds.

Performance2 As at 2025-09-30

Growth of $10,000 (Since inception date)

growth of 10k graph

Calendar year performance

annual performance graph

average annual compound returns

YTD 1 Mo 3 Mo 6 Mo 1 Y 3 Y 5 Y 10 Y Inception*
-3.49% -0.17% 1.74% -6.36% -16.69% 2.64% 1.25% 1.99% 6.68%
*Since inception date

Distribution history3

Payable date Total
2022-03-25 0.5033
2021-03-26 0.1714
2020-12-18 0.2724
2020-09-25 0.2584
2020-06-26 0.1886
Payable date Total
2020-03-20 0.4395
2019-12-13 0.2744
2019-09-27 0.3063
2019-06-21 0.2883
2019-03-22 0.4530

Management team

First we'll display the Team Company and then the Team members
Greg Quickmire
Peter Hofstra

CI Global Health Sciences Corporate Class

Series F USD
 
Portfolio allocations4 As at 2025-09-30
Asset allocation (%)
  • US Equity 82.17
  • International Equity 17.62
  • Cash and Equivalents 0.20
  • Other 0.01
Sector allocation (%)
  • Healthcare 99.79
  • Cash and Cash Equivalent 0.20
  • Other 0.01
Geographic allocation(%)
  • United States 81.26
  • United Kingdom 8.51
  • Switzerland 4.99
  • Netherlands 2.17
  • Denmark 1.99
  • Canada 1.07
  • Other 0.01
Top holdings5
Sector (%)
1. Eli Lilly and Co Drugs 11.05%
2. UnitedHealth Group Inc Healthcare Services 9.62%
3. AbbVie Inc Drugs 8.90%
4. AstraZeneca PLC Drugs 8.51%
5. Thermo Fisher Scientific Inc Healthcare Equipment 8.15%
6. Merck & Co Inc Drugs 7.89%
7. Danaher Corp Healthcare Equipment 6.86%
8. Intuitive Surgical Inc Healthcare Equipment 6.43%
9. Vertex Pharmaceuticals Inc Drugs 5.06%
10. DexCom Inc Healthcare Equipment 4.33%
11. CVS Health Corp Healthcare Services 3.19%
12. Johnson & Johnson Drugs 3.14%
13. IQVIA Holdings Inc Drugs 3.10%
14. Lonza Group AG Drugs 2.46%
15. Uniqure NV Drugs 2.17%
Over 35,000 financial advisors have chosen CI Global Asset Management as a partner. We believe that Canadians have the best opportunity for investments success by using the services of a professional financial advisor. Learn more at ci.com.